Vanguard Personalized Indexing Management LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Francis Steltz on Jun 16th, 2026

Vanguard Personalized Indexing Management LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 8.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,973 shares of the biopharmaceutical company’s stock after purchasing an additional 901 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Regeneron Pharmaceuticals were worth $9,242,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. WPG Advisers LLC increased its stake in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. Entrust Financial LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $32,000. Caitlin John LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. Finally, MCF Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.5%

Regeneron Pharmaceuticals stock opened at $614.98 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $503.25 and a 1-year high of $821.11. The firm has a market capitalization of $65.02 billion, a price-to-earnings ratio of 14.98, a P/E/G ratio of 1.34 and a beta of 0.25. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The firm has a 50 day simple moving average of $689.17 and a 200 day simple moving average of $736.78.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period in the previous year, the business earned $8.22 EPS. Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several research analyst reports. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Leerink Partners restated a “market perform” rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Finally, Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Get Our Latest Stock Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.